Cipla
- All
- News
- Videos
-
Cipla, Glenmark Recall Asthma Drugs Made In Indore From US Market
Drug makers Cipla and Glenmark are recalling products from the American market due to manufacturing issues, according to the US health regulator.
-
Cipla Recalls 6 Batches Of Bronchospasm Treatment Inhalation Aerosol In US
Pharmaceutical firm Cipla Ltd on Friday said it is voluntarily recalling six batches of Albuterol Sulfate inhalation aerosol in the US market due to container defect.
-
Why Are Pharma Stocks Rising?
The recent decline in the stock market has unnerved investors and traders alike. But pharma stocks are rising. Find out why and other implications.
-
Here's Why Cipla Share Price Is Rising
Pharma stocks are in focus amid renewed fears of Covid outbreaks and have rallied between 5-15% in the past couple of days.
-
Cipla's Profit After Tax Up 11% To Rs 789 Crore
Pharmaceutical firm Cipla has announced a 10.9 per cent growth in its profit after tax to Rs 789 crore for the quarter ended September 2022, against Rs 711 crore in the year-ago period.
-
Dr Reddy's, Cipla, Aurobindo Units Recall Products From US Market
Leading drug firms Dr Reddy's Laboratories, Cipla and Aurobindo Pharma are recalling different products in the US market for various issues, according to the US Food and Drug Administration.
-
Stocks To Watch: Bajaj Auto, Cipla, Bank Of Baroda, JSW Steel
The domestic stock indices are likely to trade lower on Tuesday, taking cues from their global peers.
-
Stocks To Watch: Nazara Tech, Wipro, Aurobindo Pharma, Cipla
The domestic stock indices are likely to trade lower on Monday, taking cues from the global markets.
-
5 Promoters Who Sold Their Holding Before The Stock Market Selloff
As economic realities of high inflation and slowing growth set in, the BSE Sensex dropped more than 10% since its January 2022 peak
-
Sensex Slips Over 100 Points, Nifty Trades Below 17,300; Cipla, Wipro, Tech Mahindra Top Drags
The Indian equity indices on Friday traded lower led by selling pressure in information technology and pharma stocks during opening deals.
-
Naina Lal Kidwai Resigns From Cipla Board
Drug major Cipla on Wednesday said that Naina Lal Kidwai has resigned as independent director on its board, with effect from March 31, 2022
-
Cipla Q3 Profit Dips 2.6% To Rs 729 Crore
Cipla on Tuesday reported a 2.6 per cent decline in its consolidated profit after tax to Rs 729 crore for the third quarter ended on December 31, 2021
-
Pharma Stocks Gain After Centre Approves Use Of COVID Pill Molnupiravir
Pharma Stocks Today: Pharmaceutical shares such as Cipla, Dr Reddy's Laboratories, Torrent Pharma, Sun Pharma Industries gained around two per cent each on Wednesday
-
Sensex Rises 296 Points, Nifty Settles Above 17,050; Tech Mahindra, Cipla, Dr Reddy's Among Top Gainers
The Indian equity benchmarks turned positive in a highly volatile trade on Monday led by gains in IT and pharma stocks.
-
Stocks To Watch: Axis Bank, Cipla, Bajaj Finance, Nippon Life
The domestic stock markets are expected to trade cautiously on Wednesday, taking cues from the global markets.
-
Cipla, Glenmark Recall Asthma Drugs Made In Indore From US Market
Drug makers Cipla and Glenmark are recalling products from the American market due to manufacturing issues, according to the US health regulator.
-
Cipla Recalls 6 Batches Of Bronchospasm Treatment Inhalation Aerosol In US
Pharmaceutical firm Cipla Ltd on Friday said it is voluntarily recalling six batches of Albuterol Sulfate inhalation aerosol in the US market due to container defect.
-
Why Are Pharma Stocks Rising?
The recent decline in the stock market has unnerved investors and traders alike. But pharma stocks are rising. Find out why and other implications.
-
Here's Why Cipla Share Price Is Rising
Pharma stocks are in focus amid renewed fears of Covid outbreaks and have rallied between 5-15% in the past couple of days.
-
Cipla's Profit After Tax Up 11% To Rs 789 Crore
Pharmaceutical firm Cipla has announced a 10.9 per cent growth in its profit after tax to Rs 789 crore for the quarter ended September 2022, against Rs 711 crore in the year-ago period.
-
Dr Reddy's, Cipla, Aurobindo Units Recall Products From US Market
Leading drug firms Dr Reddy's Laboratories, Cipla and Aurobindo Pharma are recalling different products in the US market for various issues, according to the US Food and Drug Administration.
-
Stocks To Watch: Bajaj Auto, Cipla, Bank Of Baroda, JSW Steel
The domestic stock indices are likely to trade lower on Tuesday, taking cues from their global peers.
-
Stocks To Watch: Nazara Tech, Wipro, Aurobindo Pharma, Cipla
The domestic stock indices are likely to trade lower on Monday, taking cues from the global markets.
-
5 Promoters Who Sold Their Holding Before The Stock Market Selloff
As economic realities of high inflation and slowing growth set in, the BSE Sensex dropped more than 10% since its January 2022 peak
-
Sensex Slips Over 100 Points, Nifty Trades Below 17,300; Cipla, Wipro, Tech Mahindra Top Drags
The Indian equity indices on Friday traded lower led by selling pressure in information technology and pharma stocks during opening deals.
-
Naina Lal Kidwai Resigns From Cipla Board
Drug major Cipla on Wednesday said that Naina Lal Kidwai has resigned as independent director on its board, with effect from March 31, 2022
-
Cipla Q3 Profit Dips 2.6% To Rs 729 Crore
Cipla on Tuesday reported a 2.6 per cent decline in its consolidated profit after tax to Rs 729 crore for the third quarter ended on December 31, 2021
-
Pharma Stocks Gain After Centre Approves Use Of COVID Pill Molnupiravir
Pharma Stocks Today: Pharmaceutical shares such as Cipla, Dr Reddy's Laboratories, Torrent Pharma, Sun Pharma Industries gained around two per cent each on Wednesday
-
Sensex Rises 296 Points, Nifty Settles Above 17,050; Tech Mahindra, Cipla, Dr Reddy's Among Top Gainers
The Indian equity benchmarks turned positive in a highly volatile trade on Monday led by gains in IT and pharma stocks.
-
Stocks To Watch: Axis Bank, Cipla, Bajaj Finance, Nippon Life
The domestic stock markets are expected to trade cautiously on Wednesday, taking cues from the global markets.
